SCHEMBL16320863

SCHEMBL16320863

Cc1nccc(-c2cnn(C)c2C(N)=O)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.47
CDK2 P24941 3/20 0.37
DYRK1A Q13627 3/20 0.37
DYRK1B Q9Y463 2/20 0.37
KDM4E B2RXH2 4/20 0.36
ALDH1A1 P00352 3/20 0.36
POLB P06746 1/20 0.36
GAA P10253 1/20 0.36
APOBEC3A P31941 1/20 0.36
CDK4 P11802 1/20 0.36
GSK3B P49841 1/20 0.36
MAPT P10636 2/20 0.36
TYK2 P29597 2/20 0.35
JAK2 O60674 2/20 0.35
LMNA P02545 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
PDE10A Q9Y233 1/20 0.35
HTT P42858 1/20 0.35
AR P10275 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16003806 0.87 KDM4E (0.42) TGFBR1CDK2DYRK1ADYRK1BKDM4E
SCHEMBL16352279 0.84 TGFBR1 (0.38) TGFBR1CDK2DYRK1ADYRK1BKDM4E
SCHEMBL16003794 0.84 TGFBR1 (0.38) TGFBR1CDK2DYRK1ADYRK1BKDM4E
SCHEMBL16323484 0.82 PDE10A (0.46) KDM4EALDH1A1POLBGAAAPOBEC3A
SCHEMBL16320446 0.79 TGFBR1 (0.50) TGFBR1PDE10A
SCHEMBL8227604 0.78 DYRK1A (0.41) TGFBR1CDK2DYRK1ADYRK1BKDM4E
SCHEMBL16561362 0.78 PDE10A (0.47) TGFBR1KDM4EALDH1A1POLBGAA
SCHEMBL16561138 0.77 PDE10A (0.45) TGFBR1KDM4EALDH1A1POLBMAPT
SCHEMBL18916737 0.76 MAPT (0.34) DYRK1AKDM4EALDH1A1MAPTTYK2
SCHEMBL18916805 0.75 GAA (0.41) GAALMNAPDE10AHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190071441-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US claimed
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-04-12 US claimed
US-20170217958-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US claimed
US-20170210740-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-07-27 US claimed
US-20190071441-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-20190071441-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-10174025-B2 Pyrazole derivative manufacturing method MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-01-08 US disclosed
US-10174025-B2 Pyrazole derivative manufacturing method MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2019-01-08 US disclosed
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-04-12 US disclosed
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-04-12 US disclosed
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-04-12 US disclosed
US-9902723-B2 Pyrazole derivative manufacturing method MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2018-02-27 US disclosed
US-20170210740-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-07-27 US disclosed
US-20170210740-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-07-27 US disclosed
US-20170210740-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2017-07-27 US disclosed
EP-3176167-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD Mochida Pharmaceutical Co., Ltd. (JP) 2017-06-07 EP disclosed
EP-3176168-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD Mochida Pharmaceutical Co., Ltd. (JP) 2017-06-07 EP disclosed
EP-3176168-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD Mochida Pharmaceutical Co., Ltd. (JP) 2017-06-07 EP disclosed
US-8980889-B2 Pyrazole derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-03-17 US disclosed
US-20140378448-A1 NOVEL PYRAZOLE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170217958-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A7, CYP2C19, CYP3A5 TGFBR1 3084/4885CDK2 470/4885DYRK1A 3731/4885
US-10174025-B2 Pyrazole derivative manufacturing method CYP3A5, CYP3A7, CYP3A4 TGFBR1 3118/4885CDK2 737/4885DYRK1A 3520/4885
US-20180099964-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A5, CYP3A7, CYP3A4 TGFBR1 3118/4885CDK2 737/4885DYRK1A 3520/4885
US-20170210740-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A5, CYP3A7, CYP3A4 TGFBR1 2983/4885CDK2 875/4885DYRK1A 3891/4885
US-20190071441-A1 PYRAZOLE DERIVATIVE MANUFACTURING METHOD CYP3A5, CYP3A7, CYP3A4 TGFBR1 3118/4885CDK2 737/4885DYRK1A 3520/4885
US-20140378448-A1 NOVEL PYRAZOLE DERIVATIVE PDE10A, PDE3A, PDE5A TGFBR1 2867/4885CDK2 1797/4885DYRK1A 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.